1Ab company information, Employees & Contact Information

Ventus Therapeutics Enters into a Collaboration and License Agreement with Genentech to Discover and Develop Small-Molecule Medicines Using Ventus' ReSOLVE® Platform Business Wire

Circle Pharma to Participate in Upcoming Investor Conferences Business Wire

Ventus Therapeutics to Present at Morgan Stanley 23rd Annual Global Healthcare Conference Business Wire

Aera Therapeutics Appoints Bill Querbes, Ph.D., as Chief Scientific Officer Yahoo Finance

Actio Biosciences to Participate in TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Business Wire

BlossomHill Therapeutics Presents Preliminary Findings from Phase 1/2 SOLARA Trial of BH-30643 in EGFR-mutant NSCLC at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Yahoo Finance

Aera Therapeutics Appoints Bill Querbes, Ph.D., as Chief Scientific Officer Business Wire

Circle Pharma Announces Agreement with Lilly to Further Enhance AI/ML Capabilities and Accelerate Development of New Oral Macrocycle Therapies Business Wire

Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025 Business Wire

Aera Therapeutics Presents Preclinical Data and Announces Nomination of First Development Candidate, AERA-109, a Targeted In Vivo CAR-T Therapy for B Cell-mediated Autoimmune Diseases Business Wire

Ventus Therapeutics to Present Phase 1 Results for VENT-03, a First-in-Class cGAS Inhibitor, at LUPUS 2025 Business Wire

MOMA Therapeutics to Participate in Upcoming Investor Conferences Business Wire

Circle Pharma Unveils First Preclinical Data from Cyclin D1 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Business Wire

Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition Business Wire

Marea Therapeutics Appoints Ian Clements as Chief Financial Officer Business Wire

Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology Business Wire

Mirador Therapeutics Appoints Gregg Gilbert as Chief Financial Officer Business Wire

Ventus Therapeutics Announces Nature Reviews Immunology Publication Demonstrating the Promise of Caspase-4/5 as Therapeutic Targets Business Wire

Abdera Therapeutics to Present Key Updates on its Radiopharmaceutical Development Pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting Business Wire

Metsera Reports Highly Competitive Results from Ongoing Trial of Novel, Potential Once-Monthly Injectable GLP-1 Receptor Agonist MET-097 Business Wire

Ventus Therapeutics Announces Publication in Nature’s Communications Chemistry Describing the Structure-based Optimization of a New Series of cGAS Inhibitors Business Wire

Bayer and MOMA Therapeutics Enter Collaboration and License Agreement in Oncology Business Wire

Abdera Therapeutics Expands Management Team and Board of Directors Business Wire

Ventus Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating VENT-02, an Oral, Brain-Penetrant NLRP3 Inhibitor, in Parkinson’s Disease Business Wire

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference GlobeNewswire

Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer Business Wire

Healx Announces $47 million Series C Financing and FDA Clearance of Phase 2 IND for Neurofibromatosis Type 1 Trial Business Wire

Cartography Unveils First Pipeline Program Targeting a Highly-Specific and Emerging Colorectal Cancer Antigen in Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting Business Wire

Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality Business Wire

Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases Business Wire

Actio Biosciences to Participate in Upcoming October Investor Conferences FinancialContent

Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases Business Wire

Apogee Therapeutics Strengthens Team with Appointments of Industry Leaders to Board of Directors and Management Business Wire

Maze Therapeutics to Present New Data for APOL1 Kidney Disease in Proprietary Chronic Preclinical Model Demonstrating Reversal of Albuminuria The AI Journal

Monte Rosa Therapeutics Expands Leadership Team with Appointment of Filip Janku, M.D., Ph.D., as Chief Medical Officer Business Wire

DiCE Molecules Announces $60 Million Series C-1 Financing Business Wire

Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference FinancialContent

insitro to Present at the 42nd Annual J.P. Morgan Healthcare Conference | User | poteaudailynews.com FinancialContent

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference FinancialContent

Dascena Appoints Andrew Pucher as Chief Financial Officer Business Wire